Docetaxel
- Generic Name
- Docetaxel
- Brand Names
- Taxotere, Docetaxel Accord, Docetaxel Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C43H53NO14
- CAS Number
- 114977-28-5
- Unique Ingredient Identifier
- 699121PHCA
- Background
Docetaxel is a clinically well established anti-mitotic chemotherapy medication used for the treatment of different types of cancer, including breast, ovarian, and non-small cell lung cancer. Docetaxel is a complex diterpenoid molecule and a semisynthetic analogue of paclitaxel. Docetaxel reversibly binds to microtubulin with high affinity in a 1:1 stoichiometric ratio, allowing it to prevent cell division and promote to cell death. Compared to paclitaxel, docetaxel is two times more potent as an inhibitor of microtubule depolymerization. Docetaxel binds to microtubules but does not interact with dimeric tubulin.
The use of docetaxel may lead to udesired outcomes such as hepatic impairment, hematologic effects, enterocolitis and neutropenic colitis, hypersensitivity reactions, fluid retention, second primary malignancies, embryo-fetal toxicity, and tumor lysis syndrome. Docetaxel was approved by the FDA in 1996 and is available in solution for injection for intravenous or parenteral administration.
- Indication
Docetaxel is indicated as a single agent for the treatment of locally advanced or metastatic breast cancer after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC. It is also indicated as a single agent for locally advanced or metastatic non-small cell lung cancer (NSCLC) after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC. For the treatment of metastatic castration-resistant prostate cancer, docetaxel is indicated with prednisone. Docetaxel is also indicated with cisplatin and fluorouracil for untreated, advanced gastric adenocarcinoma, including the gastroesophageal junction, and with cisplatin and fluorouracil for induction treatment of locally advanced squamous cell carcinoma of the head and neck (SCCHN).
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Locally Advanced Breast Cancer (LABC), Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Node Positive Breast Cancer, Ovarian Cancer Metastatic, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Advanced untreated gastric adenocarcinoma, Locally advanced Squamous cell carcinoma of head and neck, Locally advanced untreated non small cell lung cancer, Metastatic untreated non small cell lung cancer, Refractory, locally advanced Non small cell lung cancer, Refractory, metastatic Non small cell lung cancer, Refractory, metastatic hormone-refractory Prostate cancer
- Associated Therapies
- -
Docetaxel in Treating Older Women With Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2005-03-04
- Last Posted Date
- 2013-09-04
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 53
- Registration Number
- NCT00104624
- Locations
- 🇫🇷
Centre Henri Becquerel, Rouen, France
🇨🇭Clinique De Genolier, Genolier, Switzerland
🇫🇷C.H. Senlis, Senlis, France
Docetaxel With or Without PI-88 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
- First Posted Date
- 2005-02-08
- Last Posted Date
- 2022-06-27
- Lead Sponsor
- Cellxpert Biotechnology Corp.
- Target Recruit Count
- 98
- Registration Number
- NCT00103389
- Locations
- 🇦🇺
Alfred Hospital, Melbourne, Victoria, Australia
🇦🇺Prince Charles Hospital, Chermside, Queensland, Australia
🇦🇺Mater Medical Centre, South Brisbane, Queensland, Australia
Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma
- Conditions
- First Posted Date
- 2005-01-10
- Last Posted Date
- 2014-02-14
- Lead Sponsor
- Gynecologic Oncology Group
- Registration Number
- NCT00101127
- Locations
- 🇺🇸
Kaiser Permanente Medical Center - Los Angeles, Los Angeles, California, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Drexel University College of Medicine - Center City Hahnemann Campus, Philadelphia, Pennsylvania, United States
Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-12-09
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 20
- Registration Number
- NCT00099086
Trial of PI-88 With Docetaxel in Advanced Non-Small-Cell Lung Cancer (NSCLC)
- Conditions
- First Posted Date
- 2004-12-01
- Last Posted Date
- 2022-06-27
- Lead Sponsor
- Cellxpert Biotechnology Corp.
- Target Recruit Count
- 100
- Registration Number
- NCT00097851
- Locations
- 🇦🇺
Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
🇦🇺Nambour General Hospital, Nambour, Queensland, Australia
🇦🇺Prince Charles Hospital, Chermside, Queensland, Australia
Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial)
- Conditions
- Interventions
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2013-11-19
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 145
- Registration Number
- NCT00095875
- Locations
- 🇺🇸
Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States
🇺🇸Albert Einstein Cancer Center at Albert Einstein College of Medicine, Bronx, New York, United States
🇺🇸Eugene M. and Christine E. Lynn Cancer Institute at Boca Raton Community Hospital - Main Campus, Boca Raton, Florida, United States
Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer
- Conditions
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2018-04-10
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 36
- Registration Number
- NCT00096304
- Locations
- 🇺🇸
Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States
Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-11-02
- Last Posted Date
- 2012-10-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 939
- Registration Number
- NCT00095199
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St-Jerome, Quebec, Canada
Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-10-08
- Last Posted Date
- 2018-01-11
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 4894
- Registration Number
- NCT00093795
- Locations
- 🇺🇸
Chestnut Hill Healthcare Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Altru Cancer Center at Altru Hospital, Grand Forks, North Dakota, United States
🇺🇸Providence Cancer Center, Anchorage, Alaska, United States
S9806: Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-09-13
- Last Posted Date
- 2012-10-08
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 204
- Registration Number
- NCT00003587
- Locations
- 🇺🇸
CCOP - Montana Cancer Consortium, Billings, Montana, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.